InvestorsHub on MSN
BioNTech shares fall 5% as BNT113 cancer trial misses progression-free survival endpoint
BioNTech (NASDAQ:BNTX) shares declined 5% on Tuesday after the biotechnology company reported that its investigational mRNA ...
4don MSN
Moderna is now worth more than 3X as much as BioNTech. Which biotech stock is the smarter pick?
Is bigger always better? Not necessarily.
AHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy ...
Every $10,000 held in BioNTech SE (NASDAQ: BNTX) shrank by roughly $713 after the Company announced that its Phase 2/3 ...
BioNTech (NASDAQ: BNTX) shares fell 5% on Tuesday after the company announced that a mid-to-late-stage clinical trial for its experimental mRNA cancer drug, BNT113, missed its first major goal.
Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA ...
BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom ...
Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...
Canaccord cut its BioNTech target from USD 136.00 to USD 132.00 on October 14, 2026. Second-quarter revenue fell to EUR ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
BioNTech's BNT113 misses Phase III PFS endpoint in HPV16-positive head and neck cancer. Read the full trial update and what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results